What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of study are Internal medicine, Surgery, Oncology, Melanoma and Immunology.
Svetomir N. Markovic works mostly in the field of Internal medicine, limiting it down to concerns involving Gastroenterology and, occasionally, Hazard ratio and Survival rate.
His Oncology research includes elements of Meta-analysis, Survival analysis, Disease and Monoclonal.
His study in Melanoma is interdisciplinary in nature, drawing from both Differential diagnosis, Ipilimumab and Adjuvant therapy.
His Immunology research is multidisciplinary, relying on both Cancer and Metastasis.
Svetomir N. Markovic has researched Lymphocyte in several fields, including Stem cell and Lymphoma.
His most cited work include:
- Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials (529 citations)
- Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis (290 citations)
- Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. (259 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Oncology, Melanoma, Immunology and Surgery are his primary areas of study.
His Internal medicine research integrates issues from Gastroenterology and Pathology.
His work carried out in the field of Gastroenterology brings together such families of science as Hematopoietic stem cell transplantation, Area under the curve, Neutropenia and Hazard ratio, Confidence interval.
His Oncology study integrates concerns from other disciplines, such as Pembrolizumab, Metastatic melanoma, Clinical trial and Ipilimumab.
His studies deal with areas such as Metastasis, Disease and Immunotherapy as well as Melanoma.
The concepts of his Immunology study are interwoven with issues in Cancer and Cytotoxic T cell.
He most often published in these fields:
- Internal medicine (52.49%)
- Oncology (33.40%)
- Melanoma (30.71%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (52.49%)
- Melanoma (30.71%)
- Cancer research (18.05%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Melanoma, Cancer research, Cancer and Oncology.
Many of his studies involve connections with topics such as Gastroenterology and Internal medicine.
The various areas that Svetomir N. Markovic examines in his Melanoma study include Immunohistochemistry, Lesion, Metastasis and Disease.
His research in Cancer research intersects with topics in Bevacizumab and Immune checkpoint.
The study incorporates disciplines such as Interquartile range, Antibody, Albumin and In vivo in addition to Cancer.
His study on Oncology also encompasses disciplines like
- Chemotherapy which is related to area like Targeted therapy,
- Meta-analysis and Hazard ratio most often made with reference to Randomized controlled trial.
Between 2017 and 2021, his most popular works were:
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. (175 citations)
- Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. (80 citations)
- Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients. (58 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Svetomir N. Markovic focuses on Internal medicine, Melanoma, Immunotherapy, Oncology and Cancer research.
His study in Adverse effect, Cohort, Meta-analysis, Pembrolizumab and Resiquimod is carried out as part of his studies in Internal medicine.
His Melanoma research is multidisciplinary, incorporating elements of Chemokine, Immune system and Clinical trial, Phases of clinical research.
The Immunotherapy study combines topics in areas such as Lung cancer, Chemotherapy and Immunogenicity.
Svetomir N. Markovic focuses mostly in the field of Oncology, narrowing it down to topics relating to Hazard ratio and, in certain cases, Randomized controlled trial.
He has researched Cancer research in several fields, including Immune checkpoint, Cytotoxic T cell, CD40, T cell and Tumor necrosis factor receptor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
